Advice
following a resubmission:
desmopressin oral lyophilisate (Noqdirna®) is accepted for restricted use within NHS Scotland.
Indication under review: Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.
SMC restriction: For use in patients aged 65 years and over.
Two phase III, placebo-controlled studies demonstrated that desmopressin, at licensed doses over three months, significantly reduced the mean number of nocturnal voids and resulted in higher proportions of responders compared with placebo, in patients with nocturia.
Download detailed advice296KB (PDF)
Medicine details
- Medicine name:
- desmopressin (Noqdirna)
- SMC ID:
- 1218/17
- Indication:
- symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.
- Pharmaceutical company
- Ferring Pharmaceuticals Ltd
- BNF chapter
- Endocrine system
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 07 August 2017